RecruitingPhase 2NCT07010497

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Studying Adult hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Asan Medical Center
Intervention
irpagratinib(drug)
Enrollment
33 enrolled
Eligibility
19 years · All sexes
Timeline
20262029

Study locations (1)

Collaborators

Abbisko Therapeutics Co, Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07010497 on ClinicalTrials.gov

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adult hepatocellular carcinoma

← Back to all trials